AAAAAA

   
Results: 1-20 |
Results: 20
Endothelial nitric oxide synthase gene polymorphism in women with idiopathic recurrent miscarriage
Authors: Tempfer, C Unfried, G Zeillinger, R Hefler, L Nagele, F Huber, JC
Citation: C. Tempfer et al., Endothelial nitric oxide synthase gene polymorphism in women with idiopathic recurrent miscarriage, HUM REPR, 16(8), 2001, pp. 1644-1647
High frequency of allelic imbalance at regions of chromosome arm 8p in ovarian carcinoma
Authors: Pribill, I Speiser, P Leary, J Leodolter, S Hacker, NF Friedlander, ML Birnbaum, D Zeillinger, R Krainer, M
Citation: I. Pribill et al., High frequency of allelic imbalance at regions of chromosome arm 8p in ovarian carcinoma, CANC GENET, 129(1), 2001, pp. 23-29
Novel MUC1 splice variants are expressed in cervical carcinoma
Authors: Obermair, A Schmid, BC Stimpfl, M Fasching, B Preyer, O Leodolter, S Crandon, AJ Zeillinger, R
Citation: A. Obermair et al., Novel MUC1 splice variants are expressed in cervical carcinoma, GYNECOL ONC, 83(2), 2001, pp. 343-347
Analysis of the human progesterone receptor gene polymorphism progins in Austrian ovarian carcinoma patients
Authors: Tong, D Fabjani, G Heinze, G Obermair, A Leodolter, S Zeillinger, R
Citation: D. Tong et al., Analysis of the human progesterone receptor gene polymorphism progins in Austrian ovarian carcinoma patients, INT J CANC, 95(6), 2001, pp. 394-397
Interleukin-8 serum level shift in patients with ovarian carcinoma undergoing paclitaxel-containing chemotherapy
Authors: Mayerhofer, K Bodner, K Bodner-Adler, B Schindl, M Kaider, A Hefler, L Zeillinger, R Leodolter, S Joura, EA Kainz, C
Citation: K. Mayerhofer et al., Interleukin-8 serum level shift in patients with ovarian carcinoma undergoing paclitaxel-containing chemotherapy, CANCER, 91(2), 2001, pp. 388-393
p53-dependent radioresistance in ovarian carcinoma cell lines
Authors: Concin, N Zeillinger, C Stimpfel, M Schiebel, I Tong, D Wolff, U Reiner, A Leodolter, S Zeillinger, R
Citation: N. Concin et al., p53-dependent radioresistance in ovarian carcinoma cell lines, CANCER LETT, 150(2), 2000, pp. 191-199
p53 polymorphism at codon 72 - does it constitute a risk for squamous intraepithelial lesions and invasive cancer of the cervix in Central Europeans?
Authors: Kucera, E Tong, D Reinthaller, A Leodolter, S Zeillinger, R Sliutz, G
Citation: E. Kucera et al., p53 polymorphism at codon 72 - does it constitute a risk for squamous intraepithelial lesions and invasive cancer of the cervix in Central Europeans?, WIEN KLIN W, 112(18), 2000, pp. 817-820
Loss of heterozygosity (LOH) at p53 is correlated with LOH at BRCA1 and BRCA2 in various human malignant tumors
Authors: Tong, D Kucera, E Schuster, E Schmutzler, RK Swoboda, H Reinthaller, A Leodolter, S Zeillinger, R
Citation: D. Tong et al., Loss of heterozygosity (LOH) at p53 is correlated with LOH at BRCA1 and BRCA2 in various human malignant tumors, INT J CANC, 88(2), 2000, pp. 319-322
Detection of p53 polymorphism at codon 72 by PCR and allele-specific oligonucleotide hybridization on microtiter plates
Authors: Tong, D Kucera, E Stimpfl, M Kolbl, H Leodolter, S Zeillinger, R
Citation: D. Tong et al., Detection of p53 polymorphism at codon 72 by PCR and allele-specific oligonucleotide hybridization on microtiter plates, CLIN CHEM, 46(1), 2000, pp. 124-126
Messenger RNA determination of estrogen receptor, progesterone receptor, pS2, and plasminogen activator inhibitor-1 by competitive reverse transcription-polymerase chain reaction in human breast cancer
Authors: Tong, D Schneeberger, C Czerwenka, K Schmutzler, RK Speiser, P Kucera, E Concin, N Kubista, E Leodolter, S Zeillinger, R
Citation: D. Tong et al., Messenger RNA determination of estrogen receptor, progesterone receptor, pS2, and plasminogen activator inhibitor-1 by competitive reverse transcription-polymerase chain reaction in human breast cancer, CLIN CANC R, 5(6), 1999, pp. 1497-1502
Comparison of flow cytometry and RT-PCR for the detection of ovarian cancer cells in peripheral blood
Authors: Stimpfl, M Schmid, BC Obermair, A Tong, D Schiebel, I Gitsch, G Leodolter, S Zeillinger, R
Citation: M. Stimpfl et al., Comparison of flow cytometry and RT-PCR for the detection of ovarian cancer cells in peripheral blood, ONCOL RES, 11(8), 1999, pp. 367-373
Prognostic significance of mutations in the p53 gene, particularly in the zinc-binding domains, in lymph node- and steroid receptor positive breast cancer patients
Authors: Kucera, E Speiser, P Gnant, M Szabo, L Samonigg, H Hausmaninger, H Mittlbock, M Fridrik, M Seifert, M Kubista, E Reiner, A Zeillinger, R Jakesz, R
Citation: E. Kucera et al., Prognostic significance of mutations in the p53 gene, particularly in the zinc-binding domains, in lymph node- and steroid receptor positive breast cancer patients, EUR J CANC, 35(3), 1999, pp. 398-405
Expression of mucins and cytokeratins in ovarian cancer cell lines
Authors: Stimpfl, M Schmid, BC Schiebel, I Tong, D Leodolter, S Obermair, A Zeillinger, R
Citation: M. Stimpfl et al., Expression of mucins and cytokeratins in ovarian cancer cell lines, CANCER LETT, 145(1-2), 1999, pp. 133-141
p53 antibody response in patients with vulvar cancer
Authors: Mayerhofer, K Hefler, L Schindl, M Concin, N Frischmuth, K Leodolter, S Zeillinger, R Reinthaller, A Kainz, C
Citation: K. Mayerhofer et al., p53 antibody response in patients with vulvar cancer, ANTICANC R, 19(3B), 1999, pp. 2323-2326
Humoral p53 antibody response is a prognostic parameter in ovarian cancer
Authors: Mayerhofer, K Tempfer, C Kucera, E Hefler, L Zeisler, H Kainz, C Zeillinger, R Sliutz, G
Citation: K. Mayerhofer et al., Humoral p53 antibody response is a prognostic parameter in ovarian cancer, ANTICANC R, 19(1B), 1999, pp. 875-878
Association of in vitro invasiveness and gene expression of estrogen receptor, progesterone receptor, pS2 and plasminogen activator inhibitor-1 in human breast cancer cell lines
Authors: Tong, D Czerwenka, K Sedlak, J Schneeberger, C Schiebel, I Concin, N Leodolter, S Zeillinger, R
Citation: D. Tong et al., Association of in vitro invasiveness and gene expression of estrogen receptor, progesterone receptor, pS2 and plasminogen activator inhibitor-1 in human breast cancer cell lines, BREAST CANC, 56(1), 1999, pp. 91-97
BRCAI gene mutations in sporadic ovarian carcinomas: Detection by PCR and reverse allele-specific oligonucleotide hybridization
Authors: Tong, D Stimpfl, M Reinthaller, A Vavra, N Mullauer-Ertl, S Leodolter, S Zeillinger, R
Citation: D. Tong et al., BRCAI gene mutations in sporadic ovarian carcinomas: Detection by PCR and reverse allele-specific oligonucleotide hybridization, CLIN CHEM, 45(7), 1999, pp. 976-981
In breast cancer, amplification of the steroid receptor coactivator gene AIB1 is correlated with estrogen and progesterone receptor positivity
Authors: Bautista, S Valles, H Walker, RL Anzick, S Zeillinger, R Meltzer, P Theillet, C
Citation: S. Bautista et al., In breast cancer, amplification of the steroid receptor coactivator gene AIB1 is correlated with estrogen and progesterone receptor positivity, CLIN CANC R, 4(12), 1998, pp. 2925-2929
Anti-HER-2/neu antibodies detected in sera of patients with breast cancer,but also in healthy females
Authors: Jasinska, J Wiltschke, C Brodowicz, T Zielinski, CC Hoffmann-Sommergruber, K Zeillinger, R
Citation: J. Jasinska et al., Anti-HER-2/neu antibodies detected in sera of patients with breast cancer,but also in healthy females, EUR J CANC, 34(13), 1998, pp. 2135-2135
Concentration of vascular endothelial growth factor (VEGF) in the serum ofpatients with suspected ovarian cancer
Authors: Obermair, A Tempfer, C Hefler, L Preyer, O Kaider, A Zeillinger, R Leodolter, S Kainz, C
Citation: A. Obermair et al., Concentration of vascular endothelial growth factor (VEGF) in the serum ofpatients with suspected ovarian cancer, BR J CANC, 77(11), 1998, pp. 1870-1874
Risultati: 1-20 |